LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Inicio・Lista de Acciones・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Cerrado

SectorSanidad

215.17 -1.26

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

213.19

Máximo

216.59

Métricas clave
By Trading Economics
Ingresos	-22M -61M
Ventas	56M 214M
Margen de beneficios	-28.549
Empleados	1,017
EBITDA	-56M -53M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+31.78% upside

Dividendos
By Dow Jones
Próximas Ganancias	30 abr 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	1.7B 14B
Apertura anterior	216.43
Cierre anterior	215.17

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

157.66 / 167.29 Soporte y Resistencia

Ascendis Pharma A-S ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 feb 2026, 16:32 UTC

Ganancias

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

14 feb 2026, 22:02 UTC

Ganancias

Looking for Dividends? Consider Europe. -- Barrons.com

14 feb 2026, 09:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 feb 2026, 21:57 UTC

Ganancias

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 feb 2026, 21:20 UTC

Ganancias

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 feb 2026, 21:05 UTC

Adquisiciones, fusiones, absorciones

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 feb 2026, 20:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 feb 2026, 20:45 UTC

Charlas de Mercado

Dollar Pares Down Early Losses -- Market Talk

13 feb 2026, 20:39 UTC

Charlas de Mercado

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 feb 2026, 20:28 UTC

Charlas de Mercado

Oil Settles Week Lower -- Market Talk

13 feb 2026, 19:51 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 19:32 UTC

Charlas de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:32 UTC

Charlas de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:29 UTC

Ganancias

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 feb 2026, 18:18 UTC

Adquisiciones, fusiones, absorciones

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 feb 2026, 17:52 UTC

Ganancias

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 feb 2026, 17:16 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 17:10 UTC

Adquisiciones, fusiones, absorciones

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 feb 2026, 16:59 UTC

Ganancias

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 feb 2026, 16:39 UTC

Adquisiciones, fusiones, absorciones

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 feb 2026, 16:11 UTC

Ganancias

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 feb 2026, 16:07 UTC

Charlas de Mercado

Hungarian Forint Could Rise Further -- Market Talk

13 feb 2026, 15:54 UTC

Ganancias

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 feb 2026, 15:26 UTC

Charlas de Mercado

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 feb 2026, 15:01 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 feb 2026, 15:00 UTC

Ganancias

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 feb 2026, 14:50 UTC

Charlas de Mercado

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 feb 2026, 14:44 UTC

Ganancias

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 feb 2026, 14:22 UTC

Charlas de Mercado

Ganancias

Global Energy Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR previsión

Precio Objetivo

By TipRanks

31.78% repunte

Estimación a 12 Meses

Media 287.42 USD 31.78%

Máximo 342 USD

Mínimo 250 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.